The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TERN | +559.5% | N/A | N/A | +117% |
| S&P | +16.49% | +84.25% | +12.99% | +76% |
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
They could ride the wave of the hottest therapeutic area in the industry.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$111.00K | 46.1% |
| Market Cap | $657.21M | -6.7% |
| Market Cap / Employee | $11.14M | 0.0% |
| Employees | 59 | -10.6% |
| Net Income | -$24,635.00K | -12.3% |
| EBITDA | -$27,605.00K | -11.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $150.70M | -44.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $570.00K | -44.8% |
| Short Term Debt | $459.00K | 68.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.78% | -0.7% |
| Return On Invested Capital | -31.36% | 321.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$19,773.00K | -19.6% |
| Operating Free Cash Flow | -$19,773.00K | -19.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.29 | 0.70 | 1.00 | 2.15 | -19.77% |
| Price to Tangible Book Value | 1.29 | 0.70 | 1.00 | 2.15 | -19.77% |
| Enterprise Value to EBITDA | -5.78 | 2.96 | -1.00 | -14.28 | 27.21% |
| Return on Equity | -29.6% | -32.1% | -35.0% | -29.1% | 2.98% |
| Total Debt | $1.35M | $1.24M | $1.13M | $1.03M | -21.15% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
